Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 10/20 | 0.45 |
| ▸ | DPP8 | Q6V1X1 | 7/20 | 0.45 |
| ▸ | DPP7 | Q9UHL4 | 7/20 | 0.45 |
| ▸ | DPP9 | Q86TI2 | 5/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.40 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | FAP | Q12884 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17546274 | 0.86 | ALDH1A1 (0.56) | DPP4DPP8DPP7DPP9EPHX2 | |
| SCHEMBL17540520 | 0.84 | DPP4 (0.46) | DPP4DPP8DPP7DPP9EPHX2 | |
| SCHEMBL17540490 | 0.84 | MEN1 (0.43) | DPP4DPP8DPP7DPP9EPHX2 | |
| SCHEMBL22874689 | 0.84 | MEN1 (0.43) | DPP4DPP8DPP7DPP9EPHX2 | |
| SCHEMBL15247214 | 0.84 | MEN1 (0.43) | DPP4DPP8DPP7DPP9EPHX2 | |
| SCHEMBL15247297 | 0.82 | EPHX2 (0.42) | DPP4DPP8DPP7DPP9EPHX2 | |
| SCHEMBL22874688 | 0.82 | EPHX2 (0.42) | DPP4DPP8DPP7DPP9EPHX2 | |
| SCHEMBL15247298 | 0.82 | EPHX2 (0.42) | DPP4DPP8DPP7DPP9EPHX2 | |
| SCHEMBL22874720 | 0.80 | EPHX2 (0.58) | DPP4DPP8DPP9EPHX2MEN1 | |
| SCHEMBL15247299 | 0.80 | CYP2C19 (0.49) | DPP4DPP8DPP7DPP9EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200039960-A1 | RORC2 INHIBITORS AND METHODS OF USE THEREOF | PFIZER INC. (US) | 2020-02-06 | — | — | US | disclosed |
| EP-3428160-A1 | HETEROBICYCLOARYL RORC2 INHIBITORS AND METHODS OF USE THEREOF | Pfizer Inc (US) | 2019-01-16 | — | — | EP | disclosed |
| EP-3027603-B1 | HETEROBICYCLOARYL RORC2 INHIBITORS AND METHODS OF USE THEREOF | PFIZER (US) | 2018-07-18 | — | — | EP | disclosed |
| US-20160046597-A1 | RORC2 INHIBITORS AND METHODS OF USE THEREOF | PFIZER (US) | 2016-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200039960-A1 | RORC2 INHIBITORS AND METHODS OF USE THEREOF | RORC, RORB, RORA | DPP4 946/4885DPP8 715/4885DPP7 358/4885 |
| US-20160046597-A1 | RORC2 INHIBITORS AND METHODS OF USE THEREOF | RORC, RORB, RORA | DPP4 946/4885DPP8 715/4885DPP7 358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.